COMMUNIQUÉS West-GlobeNewswire
-
HilleVax Announces Reduction in Force
31/07/2024 - 22:00 -
Eurobio Scientific: CONCLUSION D’UN ACCORD ENTRE EUROBIO SCIENTIFIC ET UN CONSORTIUM MENÉ PAR L’ÉQUIPE D’ENTREPRENEURS ET DIRIGEANTS D’EUROBIO SCIENTIFIC, IK PARTNERS ET NEXTSTAGE AM EN VUE DU DÉPÔT D’UNE OFFRE PUBLIQUE D’ACHAT VOLONTAIRE A
31/07/2024 - 21:03 -
EUROBIO SCIENTIFIC: CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC'S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO FILE A VOLUNTARY TENDER OFFER AT A PRICE
31/07/2024 - 21:03 -
Eurobio Scientific: FIRST HALF 2024, A SOLID START TO THE FINANCIAL YEAR IN AN UNCERTAIN ENVIRONMENT // PROPOSED TENDER OFFER
31/07/2024 - 21:01 -
Eurobio Scientific : PREMIER SEMESTRE 2024, UN SOLIDE DEBUT D’EXERCICE DANS UN CONTEXTE INCERTAIN // PROJET D’OFFRE PUBLIQUE
31/07/2024 - 21:01 -
ARCPOINT ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT AND WARRANT AMENDMENTS
31/07/2024 - 20:48 -
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
31/07/2024 - 20:03 -
AMN Healthcare Launches Executive Advisory Board
31/07/2024 - 19:00 -
Betterguards Unveils New Sports Tech, The BetterGuard 2.0
31/07/2024 - 17:26 -
20 Facilities Ranked as the 2024 Most Beautiful Hospitals in the U.S.
31/07/2024 - 16:00 -
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
31/07/2024 - 15:45 -
Natural Harmony Foods Inc. Completes Financial Audits for 2022 & 2023
31/07/2024 - 15:30 -
Palisade Bio Participates in Virtual Investor “What this Means” Segment
31/07/2024 - 15:15 -
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
31/07/2024 - 15:10 -
Arch Biopartners Closes Non-Brokered Private Placement
30/07/2024 - 22:47 -
TRACON Pharmaceuticals Announces it Will Wind Down Operations
30/07/2024 - 22:44 -
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
30/07/2024 - 22:30 -
DBV Technologies présente les dernières avancées du programme Viaskin Peanut chez les enfants de 4 à 7 ans et les tout-petits de 1 à 3 ans et publie ses résultats financiers du deuxième trimestre et premier semestre 2024.
30/07/2024 - 22:30 -
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
30/07/2024 - 22:30
Pages